Pharmacogenomics-Supported Psychotropic Prescribing Trial

Last updated: September 1, 2025
Sponsor: University of Manitoba
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mental Disability

Mood Disorders

Anxiety Disorders

Treatment

Pharmacogenetic Testing

Clinical Study ID

NCT06929533
HS26637 (HS2024:279)
  • Ages > 18
  • All Genders

Study Summary

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 years or older

  • The initiation, change, dose adjustment, or augmentation of psychotropicmedication(s) is indicated

  • The treating clinician thinks PGx testing can benefit and refers the patient to thestudy

Exclusion

Exclusion Criteria:

  • Unwillingness to donate saliva samples for genetic analysis

  • History of liver or bone marrow (hematopoietic cell) transplantation

  • PGx testing results are already available

  • No personal health identification number (PHIN) is available

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Pharmacogenetic Testing
Phase:
Study Start date:
July 01, 2025
Estimated Completion Date:
December 31, 2030

Study Description

Background and Rationale: Pharmacogenomic (PGx) testing utilizes genetic information as a surrogate marker of a person's ability to process and react to drugs. This information can be used to inform medication selection and dosing, reducing the number of trials needed to choose a suitable medicine. For Manitoba healthcare providers, the only access to psychiatric PGx testing is through commercial providers, costing patients $200 to $2,300. To the best of our knowledge, no study in Manitoba has previously evaluated the feasibility of PGx testing in adult patients seeking care for mental illness.

RESEARCH OBJECTIVES: We aim to investigate the feasibility and utility of implementing PGx testing in Manitoba for adult patients seeking care for mental illness.

Primary Outcome and Measures: Feasibility will be measured along four dimensions:

  • Acceptability (satisfaction surveys - patient & clinician)

  • Practicality (testing turnaround time)

  • Implementation (clinicians' self-reported use of testing results in the prescribing decision-making process)

  • Demand (number of referrals, clinicians' self-reported intent to use testing in the future)

Secondary Outcomes and Measures:

  • Changes in global functioning and symptom severity [Clinical Global Impression (CGI)

    • Severity and Improvement; Brief Psychiatric Rating Scale (BPRS); DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure; Patient Health Questionnaire-9 (PHQ-9); General Anxiety Disorder-7 (GAD-7); Altman Self-Rating Mania Scale (ASRM); Early Psychosis Screener (EPS-26)]

  • Adverse drug experience [Frequency, Intensity, Burden of Side Effects Rating (FIBSER)]

  • Impact of PGx testing [Changes in medication prescribing and dispensing patterns; changes in healthcare utilization (e.g., inpatient length of stay, mental health resource use, and utilization of healthcare services)

Expected Outcomes: The findings from the proposed study will inform policymakers and facilitate decision-making and priority-setting related to implementing PGx-based psychotropic prescribing policies in Manitoba

Connect with a study center

  • Shared Health Facilities

    Winnipeg, Manitoba R3C 3H8
    Canada

    Site Not Available

  • University of Manitoba College of Pharmacy

    Winnipeg, Manitoba R3E 0T5
    Canada

    Site Not Available

  • Shared Health Facilities

    Winnipeg 6183235, Manitoba 6065171 R3C 3H8
    Canada

    Site Not Available

  • University of Manitoba College of Pharmacy

    Winnipeg 6183235, Manitoba 6065171 R3E 0T5
    Canada

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.